BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers. by Luqiong Liu (11537092)

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. (<b>B)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on day 22. …”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

iKIR score decreases protection associated with protective class II genotypes in T1D. by Laura Mora-Bitria (20477525)

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

Theoretical frameworks of social protection. by Na Chen (153323)

Subjects:

Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

Subjects:

Data cleaning and preparation algorithm. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). by Ayana Ablayeva (22103708)

Subjects:

Autophagy significantly increases RGCs loss. by Hongmei Qian (538647)

Subjects:

Autophagy significantly increases RGCs loss. by Hongmei Qian (538647)

Subjects: